Cargando…
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients
The aim of this study was to evaluate the association of circulating lymphocytes profiling with antibody response in cancer patients receiving the third dose of COVID-19 mRNA-BNT162b2 vaccine. Immunophenotyping of peripheral blood was used to determine absolute counts of lymphocyte subsets, alongsid...
Autores principales: | Ruggeri, Enzo Maria, Nelli, Fabrizio, Giannarelli, Diana, Fabbri, Agnese, Giron Berrios, Julio Rodrigo, Virtuoso, Antonella, Marrucci, Eleonora, Mazzotta, Marco, Schirripa, Marta, Signorelli, Carlo, Chilelli, Mario Giovanni, Primi, Francesca, Fiore, Cristina, Panichi, Valentina, Topini, Giuseppe, Silvestri, Maria Assunta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761743/ https://www.ncbi.nlm.nih.gov/pubmed/36535985 http://dx.doi.org/10.1038/s41598-022-25558-8 |
Ejemplares similares
-
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study
por: Nelli, Fabrizio, et al.
Publicado: (2023) -
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study
por: Nelli, Fabrizio, et al.
Publicado: (2022) -
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
por: Nelli, F., et al.
Publicado: (2022) -
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study
por: Nelli, F., et al.
Publicado: (2022) -
Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study
por: Nelli, F., et al.
Publicado: (2022)